Lexaria Bioscience Corp (NASDAQ:LEXX) — Market Cap & Net Worth
Market Cap & Net Worth: Lexaria Bioscience Corp (LEXX)
Lexaria Bioscience Corp (NASDAQ:LEXX) has a market capitalization of $15.12 Million ($15.12 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26000 globally and #5385 in its home market, demonstrating a -8.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lexaria Bioscience Corp's stock price $0.61 by its total outstanding shares 24787446 (24.79 Million). Review how much debt does Lexaria Bioscience Corp carry to assess the company's total debt and financial obligations.
Lexaria Bioscience Corp Market Cap History: 2015 to 2026
Lexaria Bioscience Corp's market capitalization history from 2015 to 2026. Data shows change from $118.98 Million to $15.13 Million (-17.96% CAGR).
Index Memberships
Lexaria Bioscience Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #739 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2424 of 3165 |
Weight: Lexaria Bioscience Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lexaria Bioscience Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lexaria Bioscience Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.67x
Lexaria Bioscience Corp's market cap is 21.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $230.52 Million | $40.72K | -$1.21 Million | 5661.46x | N/A |
| 2017 | $1.26 Billion | $63.64K | -$1.87 Million | 19747.69x | N/A |
| 2018 | $691.57 Million | $433.29K | -$6.60 Million | 1596.10x | N/A |
| 2019 | $284.44 Million | $222.61K | -$4.10 Million | 1277.73x | N/A |
| 2020 | $185.39 Million | $314.79K | -$3.93 Million | 588.91x | N/A |
| 2021 | $99.89 Million | $722.74K | -$4.03 Million | 138.22x | N/A |
| 2022 | $60.98 Million | $255.40K | -$7.27 Million | 238.76x | N/A |
| 2023 | $30.98 Million | $226.21K | -$6.66 Million | 136.97x | N/A |
| 2024 | $52.05 Million | $464.28K | -$5.80 Million | 112.12x | N/A |
| 2025 | $15.29 Million | $705.92K | -$11.90 Million | 21.67x | N/A |
Competitor Companies of LEXX by Market Capitalization
Companies near Lexaria Bioscience Corp in the global market cap rankings as of June 18, 2026.
Key companies related to Lexaria Bioscience Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Lexaria Bioscience Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Lexaria Bioscience Corp's market cap moved from $118.98 Million to $ 15.13 Million, with a yearly change of -17.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.13 Million | -1.05% |
| 2025 | $15.29 Million | -70.62% |
| 2024 | $52.05 Million | +68.00% |
| 2023 | $30.98 Million | -49.19% |
| 2022 | $60.98 Million | -38.96% |
| 2021 | $99.89 Million | -46.12% |
| 2020 | $185.39 Million | -34.82% |
| 2019 | $284.44 Million | -58.87% |
| 2018 | $691.57 Million | -44.97% |
| 2017 | $1.26 Billion | +445.16% |
| 2016 | $230.52 Million | +93.75% |
| 2015 | $118.98 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Lexaria Bioscience Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.12 Million USD |
| MoneyControl | $15.12 Million USD |
| MarketWatch | $15.12 Million USD |
| marketcap.company | $15.12 Million USD |
| Reuters | $15.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more